3 ms·
Yes until we get the sub-populations sorted it is going to be very hard to get anywhere with AD. Combine that with poor animal models, late diagnosis, and the n
by danieltillett 12y ago
Yes until we get the sub-populations sorted it is going to be very hard to get anywhere with AD. Combine that with poor animal models, late diagnosis, and the need for large and very long human trials it is not surprising almost all pharma companies are avoiding AD.
- neuro_imager 12y agoUm, what? Pharma continue to throw billions at AD therapy.
- danieltillett 12y agoFrom my understanding only one one major (Eli Lilly) now has a serious AD program - all the others have effectively walked away after losing tens of billions [1]. I have to say that Biogen’s antibody [2] is looking interesting. If I had to invest my own money in AD I would spend it on better early detection/sub-population classification and then on developing monoclonal antibodies targeting each sub-population. 1. http://pipeline.corante.com/archives/2014/01/23/alzheimers_therapies_a_reasonably_gloomy_update.php http://pipeline.corante.com/archives/2014/01/23/alzheimers_t... 2. http://pipeline.corante.com/archives/2015/03/20/biogens_alzheimers_data.php http://pipeline.corante.com/archives/2015/03/20/biogens_alzh...
- neuro_imager 12y agoThank you for this. Really interesting blog, hadn't seen it before. I can vouch for the fact that at least two other majors continue to invest heavily in AD diagnostics and/or therapeutics. You're right though that all have thrown a ton of money at this without much ROI yet (apart from those producing diagnostic radio-pharmaceuticals).